Breaking News Instant updates and real-time market news.

BIIB

Biogen

$304.83

4.09 (1.36%)

07:36
01/03/19
01/03
07:36
01/03/19
07:36

Biogen announces first patient enrolled in Phase 3b Nova study

The first patient has been enrolled in a global Phase 3b study evaluating the efficacy and safety of extended interval dosing, or EID, for natalizumab compared to standard interval dosing, or SID, in patients with relapsing multiple sclerosis, or MS, Biogen announced. Currently commercialized under the brand name Tysabri, natalizumab 300 mg dosed every four weeks is the only approved dosing regimen. The new study, NOVA, is a two-year, prospective, randomized, interventional, controlled, open-label, rater-blinded, international Phase 3b study that will assess the efficacy, safety and tolerability of six-week natalizumab dosing intervals in people with relapsing-remitting MS. Patients who switch to EID after one year of treatment with natalizumab SID will be evaluated in relation to patients receiving continued SID treatment. The study will enroll approximately 480 patients worldwide. The primary endpoint is the number of new or newly enlarging T2 hyperintense lesions at week 48.

  • 29

    Jan

BIIB Biogen
$304.83

4.09 (1.36%)

01/01/19
PIPR
01/01/19
NO CHANGE
Target $400
PIPR
Overweight
Biogen raised prices on MS drugs meaningfully today, says Piper Jaffray
According to Wolters Kluwer Health, Biogen took "meaningful" price increases across its multiple sclerosis franchise effective January 1, 2019, Piper Jaffray analyst Christopher Raymond tells investors in a research note titled "Starts The New Year Off With Spate of Price Increases." The timing and magnitudes of the increases are consistent with Biogen's established pattern, adds the analyst. Raymond, however, finds the company's increases this year notable, "especially in an environment of increasing drug pricing scrutiny on both the political and policy front." Biogen took a price increase of 6% for Tecfidera, 3.5% for Tysabri and 2% each for Avonex and Plegridy, he explains. Given President Trump's Drug Pricing Blueprint and his willingness to call out individual companies for price increases, the analyst thinks some investors will be surprised by Biogen's 2019 increases. He remains a buyer of Biogen shares with an Overweight rating and $400 price target. The stock closed Monday up $7.40 to $300.92.
12/21/18
12/21/18
INITIATION

Fly Intel: Top five analyst initiations
Catch up on today's top five analyst initiations with this list compiled by The Fly: 1. NXP Semiconductors (NXPI) initiated with an Overweight at Piper Jaffray. 2. Biogen (BIIB) initiated with a Buy at BTIG. 3. Allena Pharmaceuticals (ALNA) assumed with a Buy at B. Riley FBR. 4. WWE (WWE) initiated with a Hold at Loop Capital. 5. Applied Materials (AMAT) initiated with a Buy at Needham. This list is just a portion of The Fly's analyst coverage. To see The Fly's full Street Research coverage, click here.
12/21/18
BTIG
12/21/18
INITIATION
Target $362
BTIG
Buy
BTIG starts Biogen with Buy rating, $362 price target
BTIG analyst Thomas Shrader last night initiated coverage of Biogen with a Buy rating and $362 price target. The analyst sees the company as well positioned with a "history of investing in imaging approaches for R&D, a hard-nosed business culture, a focus on neuroscience, and a cash-cow stable" of multiple sclerosis drugs. Further, Shrader expects "excitement to build over the aducanumab" story as we near the first Phase 3 readouts.
12/20/18
BTIG
12/20/18
INITIATION
Target $362
BTIG
Buy
Biogen initiated with a Buy at BTIG
BTIG initiated Biogen with a Buy rating and a price target of $362.

TODAY'S FREE FLY STORIES

AMRN

Amarin

$21.49

0.55 (2.63%)

06:55
11/14/19
11/14
06:55
11/14/19
06:55
Hot Stocks
Breaking Hot Stocks news story on Amarin »

Amarin trading halted,…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 14

    Nov

  • 28

    Dec

XLNX

Xilinx

$93.33

-1.85 (-1.94%)

06:54
11/14/19
11/14
06:54
11/14/19
06:54
Conference/Events
Xilinx management to meet with Evercore ISI »

Meetings to be held in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 14

    Nov

  • 15

    Nov

  • 20

    Nov

  • 06

    Jan

  • 28

    Jan

VCEL

Vericel

$18.80

-0.41 (-2.13%)

06:52
11/14/19
11/14
06:52
11/14/19
06:52
Conference/Events
Vericel management to meet with Oppenheimer »

Meeting to be held in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 14

    Nov

ECOR

electroCore

$1.88

0.06 (3.30%)

06:51
11/14/19
11/14
06:51
11/14/19
06:51
Recommendations
electroCore analyst commentary  »

electroCore price target…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

UMBF

UMB Financial

$66.03

-0.76 (-1.14%)

06:50
11/14/19
11/14
06:50
11/14/19
06:50
Conference/Events
UMB Financial management to meet with Piper Jaffray »

Meetings to be held in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 14

    Nov

  • 15

    Nov

NVDA

Nvidia

$208.55

-1 (-0.48%)

06:50
11/14/19
11/14
06:50
11/14/19
06:50
Recommendations
Nvidia analyst commentary  »

Nvidia price target…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 14

    Nov

  • 20

    Nov

  • 06

    Jan

UBX

Unity Biotechnology

$6.56

-0.21 (-3.10%)

06:49
11/14/19
11/14
06:49
11/14/19
06:49
Conference/Events
Unity Biotechnology management to meet with Mizuho »

Meetings to be held in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 14

    Nov

  • 15

    Nov

  • 13

    Dec

TRGP

Targa Resources

$38.31

-0.5 (-1.29%)

06:47
11/14/19
11/14
06:47
11/14/19
06:47
Conference/Events
Targa Resources management to meet with RBC Capital »

Meetings to be held in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 14

    Nov

  • 15

    Nov

SACH

Sachem Capital

$4.26

-0.04 (-0.93%)

06:46
11/14/19
11/14
06:46
11/14/19
06:46
Initiation
Sachem Capital initiated  »

Sachem Capital initiated…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

TCOM

Trip.com Group

$32.74

-1.03 (-3.05%)

06:46
11/14/19
11/14
06:46
11/14/19
06:46
Recommendations
Trip.com Group analyst commentary  »

Trip.com Group should be…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

STIM

Neuronetics

$4.44

-0.39 (-8.07%)

06:44
11/14/19
11/14
06:44
11/14/19
06:44
Conference/Events
Neuronetics management to meet with BTIG »

Meeting to be held in New…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 14

    Nov

NTAP

NetApp

$60.04

-0.08 (-0.13%)

06:44
11/14/19
11/14
06:44
11/14/19
06:44
Recommendations
NetApp analyst commentary  »

NetApp price target…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 20

    Nov

  • 12

    Dec

SBH

Sally Beauty

$19.50

-0.45 (-2.26%)

06:43
11/14/19
11/14
06:43
11/14/19
06:43
Downgrade
Sally Beauty rating change  »

Sally Beauty downgraded…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 03

    Dec

SRNE

Sorrento Therapeutics

$1.58

-0.025 (-1.56%)

06:43
11/14/19
11/14
06:43
11/14/19
06:43
Conference/Events
Sorrento Therapeutics management to meet with JMP Securities »

Meeting to be held in New…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 14

    Nov

PING

Ping Identity

$16.50

-0.25 (-1.49%)

06:42
11/14/19
11/14
06:42
11/14/19
06:42
Recommendations
Ping Identity analyst commentary  »

Ping Identity price…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 19

    Nov

CACC

Credit Acceptance

$430.08

-3.57 (-0.82%)

06:40
11/14/19
11/14
06:40
11/14/19
06:40
Recommendations
Credit Acceptance analyst commentary  »

Credit Acceptance price…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

CGC

Canopy Growth

$18.52

-0.69 (-3.59%)

06:39
11/14/19
11/14
06:39
11/14/19
06:39
Earnings
Canopy Growth reports Q2 EPS (C$1.08) vs. (C$1.52) last year »

Reports Q2 revenue…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 14

    Nov

  • 19

    Nov

T

AT&T

$39.15

-0.03 (-0.08%)

, VZ

Verizon

$59.41

0.07 (0.12%)

06:39
11/14/19
11/14
06:39
11/14/19
06:39
Downgrade
AT&T, Verizon, T-Mobile, Altice USA, Comcast, Dish, Sprint rating change  »

HSBC downgrades AT&T,…

T

AT&T

$39.15

-0.03 (-0.08%)

VZ

Verizon

$59.41

0.07 (0.12%)

TMUS

T-Mobile

$78.02

0.57 (0.74%)

ATUS

Altice USA

$26.84

0.33 (1.24%)

CMCSA

Comcast

$45.21

-0.02 (-0.04%)

DISH

Dish

$35.66

-0.37 (-1.03%)

S

Sprint

$6.07

0.215 (3.67%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 18

    Nov

  • 18

    Nov

  • 19

    Nov

  • 09

    Dec

  • 09

    Dec

  • 09

    Dec

  • 10

    Dec

  • 29

    Jan

  • 30

    Jan

CSCO

Cisco

$48.44

0.06 (0.12%)

06:37
11/14/19
11/14
06:37
11/14/19
06:37
Recommendations
Cisco analyst commentary  »

Cisco price target…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 09

    Dec

  • 10

    Dec

  • 12

    Feb

LNT

Alliant Energy

$52.60

0.9 (1.74%)

06:34
11/14/19
11/14
06:34
11/14/19
06:34
Syndicate
Alliant Energy files to sell $195.6M in common stock »

Barclays Capital Inc. is…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

PXS

Pyxis Tankers

$1.01

-0.08 (-7.34%)

06:34
11/14/19
11/14
06:34
11/14/19
06:34
Earnings
Pyxis Tankers reports Q3 EPS (4c), consensus (4c) »

Reports Q3 revenue $7.3M,…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 14

    Nov

FB

Facebook

$193.20

-1.27 (-0.65%)

06:33
11/14/19
11/14
06:33
11/14/19
06:33
Periodicals
Facebook looked to buy Musical.ly in 2016, BuzzFeed News reports »

Facebook spent the second…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

REPL

Replimune Group

$13.55

-3.3 (-19.58%)

06:33
11/14/19
11/14
06:33
11/14/19
06:33
Syndicate
Replimune Group 3.678M share Secondary priced at $13.61 »

The deal size was reduced…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 14

    Nov

CERC

Cerecor

$3.28

-0.07 (-2.09%)

06:32
11/14/19
11/14
06:32
11/14/19
06:32
Earnings
Cerecor reports Q3 EPS (7c), consensus (13c) »

Reports Q3 revenue $5.6M,…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

GDS

GDS Holdings

$42.94

-0.05 (-0.12%)

06:30
11/14/19
11/14
06:30
11/14/19
06:30
Earnings
GDS Holdings reports Q3 EPS (12c), consensus (8c) »

Reports Q3 revenue…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 14

    Nov

  • 09

    Dec

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.